A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment
Phase of Trial: Phase II
Latest Information Update: 05 Jul 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Sarcoma; Uterine cancer
- Focus Therapeutic Use
- Acronyms HGUS Study
- 10 Aug 2018 Planned number of patients changed from 54 to 90.
- 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress
- 27 Sep 2016 Data from this trial will be presented at the European Society for Medical Oncology (ESMO) 2016 Congress, reported in an Ipsen media release.